| Literature DB >> 21595628 |
Dimitri P Mikhailidis1, Moses Elisaf, Manfredi Rizzo, Kaspar Berneis, Bruce Griffin, Alberto Zambon, Vasilios Athyros, Jacqueline de Graaf, Winfried März, Klaus G Parhofer, Giovam Battista Rini, Giatgen A Spinas, Gerald H Tomkin, Alexandros D Tselepis, Anthony S Wierzbicki, Karl Winkler, Matilda Florentin, Evangelos Liberopoulos.
Abstract
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.Mesh：
Substances：
Year: 2011 PMID： 21595628 DOI： 10.2174/157016111796642661
Source DB: PubMed Journal: Curr Vasc Pharmacol ISSN： 1570-1611 Impact factor: 2.719